US pharma giant Merck & Co and hospital system Mayo Clinic have announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data, ...

The Russian government has begun a procedure for the creation of the list of vital and essential drugs for 2026. It is ...

US drugmaker Eli Lilly has announced positive topline results from the landmark TOGETHER-PsO open-label Phase IIIb trial ...

Swiss pharma giant Novartis today announced that Pluvicto (plutetium-177 vipivotide tetraxetan) has received MHRA approval ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ziihera (zanidatamab) for use in adults to treat biliary tract cancer (cancer of the structures that store and ...

Shares of Theriva Biologics rocketed 48.6% to $0.29 yesterday, after it reported the out-licensing of SYN-020, to Rasayana Therapeutics, a privately-held company targeting the gut-organ axis biology ...

SpringWorks Therapeutics, a subsidiary of German drugmaker Merck KGaA, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for ...

Lonza (SWX: LONN) has bolstered its advanced synthesis offering to increase phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates.

US healthcare giant Johnson & Johnson announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.

UK-based ViiV Healthcare, the HIV specialist company majority owned by GSK, today announced final data from the LATITUDE phase III trial, confirming its long-acting injectable treatment for HIV, ...

Swedish biotech Hansa Biopharma late yesterday announced that its Biologics License Application (BLA) for imlifidase has been accepted by the US Food and Drug Administration (FDA).

A venture-backed biotechnology company developing blood-brain barrier (BBB)–penetrant antibody therapies for neurodegenerative diseases, starting with Alzheimer’s disease. Korsana’s strategy is built ...